Core Viewpoint - The article discusses the upcoming IPO of Weimai, a leading AI healthcare management company in China, which has achieved significant growth and recognition in the AI medical sector over the past decade [1][3]. Company Overview - Weimai, founded in 2015, is recognized as one of the top three full-process health management service providers in China, focusing on AI-driven healthcare solutions [4][27]. - The company has received substantial backing from major investors, including Alibaba and Tencent, since its inception [2][35]. Business Model - Weimai's core service is full-process health management, transitioning from a treatment-centered approach to a health-centered model, covering the entire patient journey from pre-illness to post-recovery [5][4]. - The company collaborates with public hospitals, providing both online and offline services, including a dedicated team of over 360 medical assistants [7][8]. Financial Performance - Weimai's revenue has shown consistent growth, with figures of 512 million RMB in 2022, 628 million RMB in 2023, and projected 653 million RMB in 2024 [13]. - The full-process management service has been the primary revenue driver, contributing 77.3%, 69.7%, and 72% of total revenue in the respective years [13]. - The company has experienced a narrowing of losses, with adjusted net losses decreasing from 233 million RMB in 2022 to 30 million RMB in 2024 [19][21]. Market Potential - The full-process management market in China is rapidly growing, with a projected market size of 614 billion RMB in 2024 and a compound annual growth rate (CAGR) of 39.3% from 2020 to 2024 [44]. - By 2030, the market size is expected to reach 3,654 billion RMB, indicating significant growth potential [45]. Future Plans - Weimai plans to enhance its AI capabilities and expand its service offerings, aiming to address the persistent pain points in the traditional healthcare system [39][40]. - The company is positioned to leverage the increasing health awareness among residents and the growing demand for chronic disease management services due to an aging population [43][44].